NRXPW
NRx Pharmaceuticals, Inc. [NRXPW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRXPW Stock Summary
Top 10 Correlated Stocks
NRXPW
In the News
NRXPW Financial details
Company Rating
-
Market Cap
22.46M
Income
-31.75M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-314.14
Forward P/E
-
PEG
162.49
P/S
-
P/B
-1674.68
P/C
-
P/FCF
-1.35
Quick Ratio
0.46
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
637.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-30.27%
-
-
-
-
SMA20
-33.33%
SMA50
14.29%
SMA100
-11.11%
Inst Own
-
Inst Trans
-
ROA
-253%
ROE
6977%
ROC
5.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.253-0.3496
52W High
-
52W Low
-
RSI
45.69
Rel Volume
-
Avg Volume
-
Volume
5.47K
Perf Week
-0.79%
Perf Month
-50.13%
Perf Quarter
-16.33%
Perf Half Y
-31.55%
-
-
-
-
Beta
0.86
-
-
Volatility
0.01%, 0.03%
Prev Close
38.42%
Price
0.0753
Change
-1.05%
Company Profile
- Market Capitalization 22.46M
- CEO Mr. Stephen H. Willard Esq.
- Headquarters Wilmington,DE,US
- IPO Date 2017-12-01
-
Website
https://www.nrxpharma.com 
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
